http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1504760-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9fa13c33b79ba86e25d61d5e3cee4f2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-63 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 |
| filingDate | 1999-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccd6309c511f967f8ca4e664097dfe83 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c1b985c098a017dd5dde0b9e67a26e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45bcf837e1d3084441e07138deb199ee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f257abe0a99b6325cc3a8c01a6f41ac |
| publicationDate | 2005-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1504760-A1 |
| titleOfInvention | Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy |
| abstract | The invention relates to the use of a compound of the fol'lowing formula (I)n nwherein R 1 represents an alkyl group having 1 to 4 carbon atoms or an arylngroup having 6 to 10 carbon atoms which is optionally substituted; R 2 and R 3 nmay be the same or different and each represents hydrogen or an alkyl groupnhaving 1 to 4 carbon atoms or R 2 and R 3 may jointly form a ring having 3 to 7ncarbon atoms; and R 4 represents a lower alkyl group which is optionallynsubstituted by aryl, cycloalkyl, or aromatic heterocyclic residue, or anpharmaceutically acceptable salt thereof for the production of anpharmaceutical agent for the prophylaxis or treatment of a disease selectednfrom the group consisting of retinal periphlebitis, Eales' disease, ischemic eyensyndrome, retinal arteriolar macroaneurysm, retinopathy associated withnhypertension or renal disease, retinal pigment epithelitis, retinal dystrophy,nmacular dystrophy, retinochoroidal atrophy, retinochoroiditis, macular edema,nretinal pigment epithelial detachment, retinal detachment, degenerativenretinoschisis, retinoblastoma, tumors of the retinal pigment epithelium,ncapillary hemangioma of the optic nerve head, ischemic optic neuropathy, andnchoked disc/papilledema. |
| priorityDate | 1998-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 297.